Key result
Anticoagulation yields no recurrence over 2 years following unprovoked subclavian DVT in a Factor V Leiden athlete.
Why the study?
Factor V Leiden mutation increases thromboembolic risk by decreasing natural anticoagulant response to activated protein C, but clinical presentations like subclavian vein thrombosis are rarely reported.
Case Report (n=1)
Highlights the importance of considering thromboembolic diseases in pediatric or young adult patients presenting with spontaneous acute limb discomfort and discoloration.
Answers are grounded in this paper and cite their sources.
May prompt thrombosis evaluation in symptomatic young athletes; case report leaves optimal anticoagulation duration open.
Factor V Leiden is a genetic condition that can decrease natural anticoagulant effect in response to activated protein C, increasing thromboembolic risk. We report a 17-year-old man, homozygous for the Factor V Leiden mutation, with sudden onset arm stiffness, pain and swelling caused by a deep vein thrombosis in the subclavian vein. Pediatricians should consider thromboembolic diseases in cases of spontaneous acute limb discomfort and discoloration with no obvious cause. Int J Clin Pediatr. 2020;9(1):1-3 doi: https://doi.org/10.14740/ijcp343
No takes yet. Share an insight, caveat, or question.
Wen et al. (2020) conducted a case report in Subclavian vein thrombosis and Factor V Leiden mutation (n=1). Low molecular weight heparin followed by oral anticoagulation was evaluated on Recurrence of thromboembolic disease or post-phlebitic syndrome. A 17-year-old male athlete homozygous for the Factor V Leiden mutation developed an unprovoked subclavian deep vein thrombosis and had no recurrence over 2 years of anticoagulation therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: